Effect of the Omentectomy on the Hyperglycemia and the Resistance to the Insulin in Patients With Morbid Obesity

PHASE 1 The Effect of the Omentectomy on the Hyperglycemia and the Resistance to the Insulin in Patients With Morbid Obesity

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00454597

Acronym

omentectomy

Enrollment

Registered

2007-04-02

Start date

2007-02-28

Completion date

2007-12-31

Last updated

2008-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Diabetes Mellitus Type 2

Brief summary

To determine if the omentectomy diminishes hyperglycemia and improves the resistance to the insulin in patients with morbid obesity and propensity to develop to Diabetes Mellitus type 2.

Detailed description

To determine the Blood levels of glucose, curve of tolerance to the glucose, hemoglobin glycosylated, insulin, triglyceride, cholesterol, HDL, LDL, leptin and Adiponectin in patients with Obesity Morbid and that will be put under umbilical surgery and cholecystectomy opened. To put under them umbilical surgery or Cholecystectomy open with and without omentectomy To compare the Blood levels of of glucose, curve of tolerance wing glucose, hemoglobin glycosylated, insulin, triglyceride, cholesterol, HDL, LDL, leptin and Adiponectin before and after the procedure

Interventions

PROCEDUREomentectomy

surgery omentectomy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* All the patients with Obesity Morbid who suffer of hernia umbilical Chronic Cholecystitis Lithiasic non worsened. * Patient with age between the 18 to 55 years of age. * Both sorts. * Patient with index of corporal mass from 30 to 35. * Patient with index waist greater or equal hip of 100cm in men and women greater of 88cm. * Patient that has a central glucose of 100 to 125mg. * Patient that has a tolerance to the glucose of 140 to 200mg. * Patient which they have a result of triglyceride in blood of 300 or greater. * Patient that has values of LHD below 40 mg/dl.

Exclusion criteria

* Patient that they have I diagnose already established of Diabetes Mellitus type 2 and in medical treatment. * Patient with elevation of hepátic enzymes (more than 50% of the superior limits of normality) and/or creatinin in 1,5 serum \> mg/Dl. * Patient with Diabetic ketoacidosis history. * Uso of oral anticoagulants. * Positive Test of pregnancy (Human Chorionic Gonadotropin ) for women. * Recurrent Infections and at the time of the study. * Umbilical Hernia complicated and strangled or Worsened Chronic Cholecystitis.

Design outcomes

Primary

Measure	Time frame
To compare the Blood levels of of glucose, curve of tolerance wing glucose, hemoglobin glycosylated, insulin, triglyceride, cholesterol, HDL, LDL, leptin and Adiponectin before and after the procedure	3 months

Secondary

Measure	Time frame
To evaluate the metabolic conditions of the subjects of both groups to the 15 days and the month, 6, 12 and 24 months later to the procedure	3 months

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026